目的:本研究旨在评估欧洲经济区(EEA)和美国接种COVID-19疫苗后急性肾损伤(AKI)和肾衰竭(RF)的报告率(RR)。
方法:我们分别在第52/2020周和第52/2022周或第1/2023周检索并分析了报告给EudraVigilance和VAERS的COVID-19疫苗接种后可疑AKI和RF病例和死亡的药物警戒数据。估计每百万接种疫苗剂量的报告率为95%置信区间。
结果:总计,4,244例AKI和1,557例RF疑似病例在研究期间被告知EudraVilance(1,692例AKI/971RF)和VAERS(2,552例AKI/586RF),之后服用超过16亿剂COVID-19疫苗(EEA:970,934,453/US:666,511,603)。AKI的总RR为3.03(95%CI:2.94-3.12),RF每百万接种疫苗的总RR为1.11(95%CI:1.06-1.17)。在受试者中发现了统计学上显着增加风险的指数,尤其是男性,与18-64岁相比,≥65岁(AKI:OR=7.23,95%CI:6.63-7.88,p=0.000,RF:OR=4.74,95%CI:3.99-5.63,p<0.001)。美国的AKI报告率较高,而欧洲的RF报告率较高。这两种潜在的副作用在载体疫苗而不是mRNA疫苗后都升高,AD26年后的报告率最高。COV2.美国的S疫苗接种(AKI:RR=12.24,95%CI:10.66-13.81;RF:RR=3.17,95%CI:2.36-3.97)。每百万疫苗剂量有1,312例可能与AKI相关的死亡(RR=0.94,95%CI:0.89-0.99)和460例可能与RF相关的死亡(RR=0.33,95%CI:0.30-0.36)。欧洲的死亡率低于美国(AKI:OR=0.25,95%CI:0.22-0.28,p<0.001;RF:OR=0.82,95%CI:0.69-0.99,p=0.036)。
结论:接种COVID-19疫苗后很少观察到AKI和RF。需要进一步的研究来证实这些发现并揭示潜在的病理生理机制。
The present study aimed to estimate the reporting rates (RRs) of acute kidney injury (AKI) and renal failure (RF) after COVID-19 vaccination in the European Economic Area (EEA) and the United States.
We retrieved and analyzed pharmacovigilance data on suspected AKI and RF cases and fatalities post COVID-19 vaccination with licensed vaccines reported to EudraVigilance and VAERS between week 52/2020 and week 52/2022 or week 1/2023, respectively. Reporting rates with 95% confidence intervals were estimated per million administered vaccine doses.
In total, 4,244 AKI and 1,557 RF suspected cases were notified to EudraVigilance (1,692 AKI/971 RF) and VAERS (2,552 AKI/586 RF) during the study period following the administration of >1.6 billion COVID-19 vaccine doses (EEA: 970,934,453/US: 666,511,603). The overall RRs were 3.03 (95 % CI: 2.94-3.12) for AKI and 1.11 (95 % CI: 1.06-1.17) for RF per million administered vaccine doses. Indices for statistically significant increased risks were found in subjects, especially males, ≥65 years compared to 18-64 years old (AKI: OR = 7.23, 95 % CI: 6.63-7.88, p = 0.000, and RF: OR = 4.74, 95 % CI: 3.99-5.63, p < 0.001). AKI reporting rates were higher in the US, while RF reporting rates were higher in Europe. Both potential side effects were elevated following vectored rather than mRNA vaccines, with the highest reporting rates post AD26.COV2.S vaccination in the US (AKI: RR = 12.24, 95 % CI: 10.66-13.81; RF: RR = 3.17, 95 % CI: 2.36-3.97). There were 1,312 deaths possibly associated with AKI (RR = 0.94, 95 % CI: 0.89-0.99) and 460 deaths possibly associated with RF (RR = 0.33, 95 % CI: 0.30-0.36) per million vaccine doses. Fatalities were lower in Europe than in the US (AKI: OR = 0.25, 95 % CI: 0.22-0.28, p < 0.001; RF: OR = 0.82, 95 % CI: 0.69-0.99, p = 0.036).
AKI and RF may be observed rarely following vaccination against COVID-19. Further studies are warranted to confirm these findings and uncover the underlying pathophysiological mechanism.